Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cochrane Evaluates Efficacy of Cancer Pain Meds

Cochrane; 2017 Jul 6; Wiffen, et al/Jul 12; Derry, et al/Jul 12; Wiffen, et al

3 recent Cochrane reviews evaluated how well various medications treat cancer pain. Among the findings:

  • Morphine-like drugs: 95% people with moderate or severe pain who are given opioids and can tolerate them should have that pain reduced to mild or no pain within 14 days. However, most will experience adverse events (152 studies, more than 13,000 individuals).
  • Paracetamol: There is no high-quality evidence to support or refute the use of paracetamol alone or in combination with opioids for the first 2 steps of the 3-step WHO cancer pain ladder (3 studies, 122 participants).
  • Oral nonsteroidal anti-inflammatory drugs: There is no high-quality evidence to support or refute the use of NSAIDs alone or in combination with opioids for the 3 steps of the WHO cancer pain ladder (11 studies, nearly 1,000 participants).

Citation:

Wiffen PJ, Wee B, Derry S, Bell RF, Moore R. Opioids for cancer pain—an overview of Cochrane reviews. Cochrane Database of Systematic Reviews. 2017, Issue 7. Art. No.: CD012592. doi:10.1002/14651858.CD012592.pub2.

Derry S, Wiffen PJ, Moore R, McNicol ED, Bell RF, Carr DB, McIntyre M, Wee B. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database of Systematic Reviews. 2017, Issue 7. Art. No.: CD012638. doi:10.1002/14651858.CD012638.pub2.

Wiffen P, Derry S, Moore R, et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews. 2017, Issue 7. Art. No.: CD012637. doi:10.1002/14651858.CD012637.pub2.

This Week's Must Reads

Does Integrated Delivery Treatment Impact Cost? , J Oncol Pract; ePub 2018 Feb 13; Kaye, Min, et al

Anticancer Agent Dose Rounding Cost Impact Assessed, J Oncol Pract; ePub 2018 Feb 5; Fahrenbruch, et al

Employment in Patients with Early-Stage BC Studied , Cancer; ePub 2018 Feb 13; Ekenga, Pérez, et al

Program’s Impact on CRC Screening in Uninsured , Cancer; ePub 2018 Feb 7; Eberth, Thibault, et al

Charting the Landscape of Oncology Pathway Vendors , J Oncol Pract; ePub 2018 Feb 7; Daly, Zon, et al

Must Reads in Preventive Care

Predicting Acute Kidney Injury Risk from Cisplatin , J Clin Oncol; ePub 2018 Jan 10; Motwani, et al

ASCO Guideline on Alcohol Consumption and Cancer, J Clin Oncol; 2018 Jan; LoConte, Brewster, et al

Cochrane on Corticosteroids for Nausea, Vomiting, Cochrane; 2017 Jul 3; Vayne-Bossert, et al

Cochrane Evaluates Efficacy of Cancer Pain Meds, Cochrane; 2017 Jul 6; Wiffen, et al/Jul 12; Derry, et al/Jul 12; Wiffen, et al

Do Genomic Testing Cancer Risk Results Alter Behavior?, J Clin Oncol; ePub 2016 Dec 12; Gray, et al